騰盛博藥(02137.HK)向健康元集團授予新藥BRII-693大中華區獨家許可
騰盛博藥(02137.HK)宣佈,旗下全資子公司騰盛博藥美國與健康元集團簽訂知識產權許可及技術轉移協議,授予健康元集團在中國大陸、香港、澳門和臺灣等大中華地區,研究、開發和商業化新藥BRII-693的獨佔許可。
根據協議,健康元將全面負責BRII-693在大中華區的開發、監管審批和商業化。騰盛博藥美國已收取首付款,未來在達成相關里程碑事件時,將收到額外的開發和商業化里程碑付款,並將根據BRII-693的產品淨銷售額按約定比例獲得銷售分成。
BRII-693是一種在研新型合成脂(月太),用於治療多重耐藥和廣泛耐藥(MDR/XDR)革蘭氏陰性菌感染的重症患者。騰盛博藥已從國家藥監局藥品審評中心取得臨牀試驗許可,獲準在中國開展BRII-693的一期藥代動力學橋接研究,以支持未來在醫院獲得性細菌性肺炎/呼吸機相關細菌性肺炎患者中開展三期註冊性試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.